Anticonvulsant efficacy of l-deprenyl (selegiline) during chronic treatment in mice: Continuous versus discontinuous administration

Neuropharmacology

Volumn 37, Issue 12, 1998, Pages 1587-1593

  Löscher, Wolfgang ^a   Lehmann, Holger ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Dopamine; Epilepsy; Monoamine oxidase; Seizures

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTICONVULSIVE AGENT; DOPAMINE; PENTETRAZOLE; SELEGILINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; EPILEPSY; MALE; MINIPUMP; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; SEIZURE THRESHOLD; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED STRAINS; PENTYLENETETRAZOLE; RATS; SEIZURES; SELEGILINE; TIME FACTORS;

EID: 0032403232     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00130-0     Document Type: Article

References (32)

1. Anonymous, 1996. Selegiline. Drugs Fut. 21, 225.
2. Berry M.D., Juorio A.V., Paterson I.A. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurological and psychiatric disorders. Prog. Neurobiol. 44:1994;141-161.
3. Celada P., Artigas F. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues. J. Neurochem. 61:1993;2191-2198.
4. Ekstedt B., Magyar K., Knoll J. Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment? Biochem. Pharmacol. 28:1978;919-923.
5. Fang J., Yu P.H. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology. 33:1994;763-768.
6. Gerlach M., Riederer P., Youdim M.B.H. The molecular pharmacology of L-deprenyl. Eur. J. Pharmacol.-Mol. Pharm. 226:1992;97-108.
7. Gerlach M., Youdim M.B.H., Riederer P. Pharmacology of selegiline. Neurology. 47:1996;S137-S145.
8. Heinonen E.H., Anttila M.I., Lammintausta R.A.S. Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther. 56:1994;742-749.
9. Hsu K.S., Huang C.C., Su M.T., Tsai J.J. L-Deprenyl (selegiline) decreases excitatory synaptic transmission in the rat hippocampus via a dopaminergic mechanism. J. Pharmacol. Exp. Ther. 279:1996;740-747.
10. Huang C.C., Tsai J.J., Hsu K.S. L-Deprenyl (selegiline) limits the repetitive firing of action potentials in rat hippocampal CA1 neurons via a dopaminergic mechanism. Brain Res. 753:1997;27-35.
11. Kilian M., Frey H.-H. Central monoamines and convulsive thresholds in mice and rats. Neuropharmacology. 12:1973;681-692.
12. Knoll J. On the dual nature of monoamine oxidase. Horiz. Biochem. Biophys. 5:1978;37.
13. Knoll J. The pharmacology of (-)deprenyl. J. Neural Trans. 22(Suppl.):1986;75-89.
14. Knoll J. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans - a personal view. Pharmacol. Toxicol. 70:1992;317-321.
15. Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol. Toxicol. 82:1998;57-66.
16. Knoll J., Miklya I. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch. Int. Pharmacodyn. Ther. 328:1994;1-15.
17. Knoll J., Miklya I., Knoll B., Marko R., Kelemen K. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, ((-)PPAP) , act primarily as potent stimulants of action potential transmitter release coupling in the catecholaminergic neurons. Life Sci. 58:1996;817-827.
18. Lange K.W., Riederer P., Youdim M.B.H. Biochemical actions of 1-deprenyl (selegiline). Clin. Pharmacol. Ther. 56:1994;734-741.
19. Löscher W. New visions in the pharmacology of anticonvulsion. Eur. J. Pharmacol. 342:1998;1-13.
20. Löscher W., Hönack D. Anticonvulsant and antiepileptogenic effect of L-deprenyl (selegiline) in the kindling model of epilepsy. J. Pharmacol. Exp. Ther. 274:1995;307-314.
21. Löscher W., Lehmann H. L-Deprenyl (selegiline) exerts anticonvulsant effects against different seizure types in mice. J. Pharmacol. Exp. Ther. 277:1996;1410-1417.
22. Löscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2:1988;145-181.
23. Löscher W., Hönack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drug. III. Pentylenetetrazol seizure models. Epilepsy Res. 8:1991;171-189.
24. Magyar, K., 1993. Pharmacology of monoamine oxidase B inhibitors. In: Szelenyi, I. (Ed.), Inhibitors of Monoamine Oxidase B. Pharmacology and Clinical Use in Neurodegenerative Disorders. Birkhäuser, Basel, p. 125.
25. Magyar K., Tóthfalusi L. Pharmacokinetic aspects of deprenyl effects. Pol. J. Pharmacol. Pharm. 36:1984;373-384.
26. Mahmood I., Marinac J.S., Willsie S., Mason W.D. Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. Biopharm. Drug Dispos. 16:1995;535-545.
27. Olanow C.W. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. J. Neural Transm.-Suppl. 48:1996;75-84.
28. Oxenkrug G.F., Requintina P.J., Correa R.M., Yuwiler A. The effect of 6-months L-deprenyl administration on pineal MAO-A and MAO-B activity and on the content of melatonin and related indoles in aged female Fisher 344N rats. J. Neural Trans. 41(Suppl.):1994;249-252.
29. Przegalinski, E., 1985. Monoamines and the pathophysiology of seizure disorders. In: Frey, H.-H., Janz, D. (Eds.), Antiepileptic Drugs. Springer, Berlin, p. 101.
30. Schneider L.S., Tariot P.N., Goldstein B. Therapy with L-deprenyl (selegiline) and relation to abuse liability. Clin. Pharmacol. Ther. 56:1994;750-756.
31. Tatton W.G., Chalmersredman R.M.E. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 47:1996;S171-S183.
32. Tatton W.G., Wadia J.S., Ju W.Y.H., Chalmersredman R.M.E., Tatton N.A. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J. Neural Transm.-Suppl. 48:1996;45-59.